Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2021-07-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于收到政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (811 characters) from a company disclosing receipt of government subsidies, detailing amounts and accounting treatment. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about government grants received, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2021-07-08 Chinese
圣湘生物科技股份有限公司独立董事关于上海证券交易所《关于对圣湘生物科技股份有限公司收购股权有关情况的问询函》的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion regarding an inquiry letter from the Shanghai Stock Exchange about a share acquisition transaction by 圣湘生物科技股份有限公司. It discusses the fairness of the transaction pricing, impact on company finances, and protection of shareholder interests. The document is short (817 characters) and primarily provides an opinion on a regulatory inquiry related to a capital transaction. It does not contain financial statements or detailed financial data, nor is it a full report or announcement of voting results. It is not a certification letter but an independent opinion related to a regulatory inquiry. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2021-06-25 Chinese
西部证券股份有限公司关于上海证券交易所关于对圣湘生物科技股份有限公司收购股权有关情况的问询函的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure and response related to a transaction involving the acquisition of a minority equity stake (14.77%) in a company named 真迈生物 (Zhenmai Bio). It includes extensive financial data for the target company over multiple years, descriptions of products, technologies, patents, team, competitors, and strategic rationale for the investment. The document references regulatory requirements and includes a sponsor's (西部证券) verification opinion. The content is focused on the transaction details, valuation, strategic cooperation, and business overview of the target company. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is not a proxy, voting result, or remuneration report. It is a regulatory disclosure related to a capital investment transaction and includes detailed information to comply with regulatory inquiries and disclosure rules. The document is lengthy (15,000 characters) and contains substantive financial and business information about the transaction and the target company. This fits best with the category "Capital/Financing Update (CAP)" which covers updates on company fundraising, financing activities, or capital structure changes. Therefore, the filing type code is CAP with high confidence.
2021-06-25 Chinese
圣湘生物科技股份有限公司关于收购股权有关情况问询函的回复公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement and response regarding an equity acquisition inquiry related to Shenzhen Zhenmai Bio-Technology Co., Ltd. It includes extensive financial data of the target company over multiple years, descriptions of products, R&D, core technologies, team, competitors, patents, and strategic cooperation details. The document is lengthy (15,000 characters) and contains substantive financial data, business descriptions, and strategic rationale for the investment. It is not a simple announcement or a brief summary but a comprehensive disclosure related to a capital investment transaction. The content focuses on the acquisition of a minority equity stake (14.77%) in a company, with detailed financial and operational information to justify the transaction price and strategic fit. This fits best under the category of Capital/Financing Update (CAP), as it relates to a financing activity and equity acquisition with detailed financial and strategic information. It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2021-06-25 Chinese
圣湘生物科技股份有限公司关于收到收购股权有关情况的问询函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding a regulatory inquiry letter (问询函) received from the Shanghai Stock Exchange's Sci-Tech Innovation Board (科创板) about the company's equity acquisition. The text includes the full content of the inquiry letter, which requests detailed disclosures about the acquisition, including financial data, strategic rationale, and related party relationships. The document is relatively short (1454 characters) and serves as a public announcement of the inquiry and the company's intention to respond. It does not contain actual financial statements, audit results, or detailed management analysis, but rather is a regulatory announcement related to a specific transaction inquiry. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-21 Chinese
圣湘生物科技股份有限公司自愿披露关于收购股权、对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 圣湘生物科技股份有限公司 regarding its voluntary disclosure about an equity acquisition and external investment. It includes comprehensive information about the transaction, parties involved, pricing, contractual terms, impact on the company, and risk warnings. The content focuses on a capital investment transaction involving share acquisition and capital increase, with detailed financial and legal descriptions. It is not a full financial report, earnings release, or management discussion, but rather an announcement about a financing and capital structure change. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple regulatory filing, but a substantive update on financing activity.
2021-06-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.